secwatch / observer
8-K filed September 12, 2023, 7:59 PM ET ticker JAZZ CIK 0001232524
leadership confidence high sentiment neutral materiality 0.60

Jazz Pharma President & COO Swisher to retire; CFO Galá promoted to COO; interim CFO named

Jazz Pharmaceuticals plc

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Patricia Carr

principal financial officer (interim)
JAZZ · Jazz Pharmaceuticals plc
Effective
2023-10-01
Filed
September 12, 2023, 7:59 PM ET
Effective as of October 1, 2023, Patricia Carr, the Company’s Senior Vice President and Chief Accounting Officer, will serve as the Company’s principal financial officer on an interim basis while the Company conducts a search for Ms. Galá’s replacement as the Company’s Executive Vice President and Chief Financial Officer.
Departed

Daniel Swisher, Jr.

President and Chief Operating Officer
JAZZ · Jazz Pharmaceuticals plc
Effective
2023-10-01
Successor
Renée Galá
Filed
September 12, 2023, 7:59 PM ET
Mr. Swisher will cease performing the duties and responsibilities of the Company’s President and Chief Operating Officer and will resign from any office or directorship at any affiliated entity of the Company, effective October 1, 2023.
Role change

Renée Galá

President and Chief Operating Officer
JAZZ · Jazz Pharmaceuticals plc
Effective
2023-10-01
Filed
September 12, 2023, 7:59 PM ET
On September 11, 2023, the Board appointed Renée Galá as the Company’s President and Chief Operating Officer, effective as of October 1, 2023, to succeed Mr. Swisher as the Company’s President and Chief Operating Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Patricia Carr was appointed as principal financial officer (interim) at Jazz Pharmaceuticals plc.

Action
will serve as
Role
principal financial officer (interim)
Exact text from the filing
Effective as of October 1, 2023, Patricia Carr, the Company’s Senior Vice President and Chief Accounting Officer, will serve as the Company’s principal financial officer on an interim basis while the Company conducts a search for Ms. Galá’s replacement as the Company’s Executive Vice President and Chief Financial Officer.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Daniel Swisher, Jr. departed as President and Chief Operating Officer at Jazz Pharmaceuticals plc.

Action
resign
Role
President and Chief Operating Officer
Exact text from the filing
Mr. Swisher will cease performing the duties and responsibilities of the Company’s President and Chief Operating Officer and will resign from any office or directorship at any affiliated entity of the Company, effective October 1, 2023.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Renée Galá was appointed as President and Chief Operating Officer at Jazz Pharmaceuticals plc.

Action
appointed
Role
President and Chief Operating Officer
Exact text from the filing
On September 11, 2023, the Board appointed Renée Galá as the Company’s President and Chief Operating Officer, effective as of October 1, 2023, to succeed Mr. Swisher as the Company’s President and Chief Operating Officer.
View on SEC.gov

Jazz Pharmaceuticals plc filing history →

Source: SEC EDGAR
accession 0001193125-23-233019
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.